

Physicians' Perspectives on Antibiotic Use in Pediatric and Adult RTIs: A Nationwide Multicenter Survey


Presenter – Dr. Amitrajit Pal

Co-authors – Dr. Ajitkumar Gondane, Dr. Dattatray Pawar, Dr. Akhilesh Sharma **Department/Institute** – Medical Affairs, Alkem Laboratories Ltd., Mumbai, India

INTRODUCTION

- Burden: RTIs cause >17 billion cases/year, ~20% of consultations, and ~4 million deaths annually.
- ➤ India: URTIs affect 2.8% of children <5 years; pneumonia causes ~16% of under-5 deaths.
- > Antibiotic use: 40–60% of RTI cases get antibiotics unnecessarily.
- ➤ Trends: Adults Amoxicillin-Clavulanate (~45%); Paediatrics Macrolides (30–35%).
- ➤ Gap: Wide variability in prescribing; limited data on syrup vs. tablet use; no large multicentre evaluation
- > Objectives:
 - Evaluate HCP opinions on syrup vs. tablet antibiotics in paediatric and adult RTIs.
 - Assess attitudes towards antibiotic management across age groups.
 - Identify concerns, challenges, and factors influencing prescription decisions

RTIs: A Significant Health Burden



RATIONALE


- Wide variability in antibiotic prescriptions across healthcare facilities.
- Lack of consistent and suitable prescribing practices increases risk of resistance.
- > Limited evidence on syrup vs. tablet formulations in paediatric vs. adult RTIs.
- ➤ Need for a **nationwide multicentre evaluation** to understand real-world decision-making and improve quality of care.

ANTIMICROBIAL RESISTANCE

- ➤ Rising AMR burden: ~5 million global deaths linked to AMR; ~297,000 in India.
- > RTIs drive misuse: 40–60% of RTI cases get unnecessary antibiotics; resistance increasing in S. pneumoniae.
- > Study contribution: Captures real-world prescribing patterns (syrup vs. tablet; adult vs. paediatric) across ~15,000 HCPs.
- Impact: Provides evidence to inform guidelines, CME, and stewardship for rational RTI antibiotic use.

METHODOLOGY


- > **Design:** Nationwide, multicentre, cross-sectional, questionnaire-based survey.
- Participants: Qualified medical practitioners (General Physicians, Paediatricians, ENT Surgeons, Consulting Physicians).
- > Tool: 16-question structured survey administered electronically.
- > Duration: ~6 months for study completion.
- Analysis: Descriptive statistics (mean, median, SD, frequencies);




RESULTS

- > Participants (n): 2,539 HCPs.
- ➤ Most affected age group: Children 0–10 years (26.9%).
- > Common presentations:
 - Acute Otitis Media 36.7%
 - Bacterial Sinusitis 21.9%
 - Community-Acquired Pneumonia 20.4%
- First-line antibiotic: Co-Amoxiclav (94%).
- Reasons: efficacy (61.4%), safety (25%).
- ➤ **Guideline adherence:** Influenced prescribing in 56.4%.
- > Antimicrobial susceptibility testing: Used by 62.4%.
- > Treatment failure management:
 - Dose escalation 45.8%
 - Switch to High-dose co-amoxiclav 40.2%
 - Switch to Cefpodoxime 33.8%
- Dosing adjustment: Weight-based in 75.9%.
- Most reported adverse event: Diarrhoea (17.8%).

Clinical Diagnosis





CONCLUSION

- Co-Amoxiclav continues to be the cornerstone of RTI management among Indian HCPs, aligning with guideline recommendations and supported by strong clinical evidence.
- Prescribing decisions appear rational, with physicians factoring in age, comorbidities, and clinical presentation rather than relying solely on empirical habits.
- This reflects a mature, evidence-informed approach, demonstrating awareness of resistance patterns and the need for appropriate spectrum coverage.
- However, continued medical education and robust stewardship programs remain essential to ensure uniformity across practices, minimize misuse, and preserve antibiotic efficacy for the future.

REFERENCES

- Jin X, Ren J, Li R, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. eClinicalMedicine. 2021;37:100986. doi:10.1016/j.eclinm.2021.100986
- National Family Health Survey (NFHS-5), 2019-21. : International Institute for Population Sciences (IIPS); 2021.
- Liu L, Chu Y, Oza S, et al. National, regional, and state-level all-cause and cause-specific under-5 mortality in India in 2000–15: a systematic analysis with implications for the Sustainable Development Goals. Lancet Glob Health. 2019;7(6):e721-e734. doi:10.1016/S2214-109X(19)30080-4